

# Candriam Sustainable Equity Europe

## Market Overview

Global stock markets took a breather in August, after reaching a high for the year at the end of July. The underlying macro-economic data confirmed a resilient US economy, a strong economy in Japan and a slightly weaker economy in Europe. Meanwhile, the Chinese economy seems to have a hard time to recover and convince the investment community, despite government measures.

Eurostat's flash GDP estimate showed that the euro zone GDP grew in the second quarter of the year. While this pace was relatively modest, the labour market remains very tight, with the unemployment rate dropping in June, its lowest level on record. However, the economic outlook remains uncertain, as the August composite PMI fell to 47, its lowest level (ex-Covid) since 2012.

Unsurprisingly, euro zone headline inflation defied expectations and remained flat in August. Core inflation, however, did fall modestly. While improving, inflation nevertheless remains well above the European Central Bank (ECB)'s target and markets continue to price further ECB rate increases before the end of the year.

The Q2 earnings season is mostly over without having an important positive or negative impact (results and guidance were more or less in line with expectations).

## Portfolio Highlights

Our performance was negative relative to the MSCI Europe in August.

Our main positive contributors were Consumer discretionary (underweight sector allocation effect, absence from the automotive sector) and Consumer staples (Beiersdorf, Reckitt).

Our main detractors were Healthcare (Novo Nordisk, Carl Zeiss, Sartorius Stedim) and Financials (KBC, Fineco, Intesa San Paolo).

Our main transactions :

- In Financials, we reduced Intesa San Paolo following the Italian bank tax announcement.
- In Industrials, we slightly increased Spirax-Sarco after the reset of expectations on two end markets with destocking issues: biopharma and semiconductors. The exact timing and magnitude of the recovery remain uncertain but the ingredients for growth and profitability remain in place (direct sales model, self-generating growth ahead of global industrial production, pricing power, decarbonization opportunity...).

## Outlook

Even if we are closer to the pick, it is still tough to call for how long the FED and the ECB will need to keep very restrictive funding conditions. Core inflation is still too high and the employment markets in both regions are tight. The "Pivot" of the FED (flexibility to inject liquidity) should be observed later in 2024 and more probably in H2. The ECB will follow the FED with a time lag.

Concerning the 10Y US and German Government yields, we should have reached a long-term top, which is very positive for growth sectors and stocks (e.g. Information Technology). The *growth* style has been outperforming the *value* style YTD. We expect the momentum of growth stocks to accelerate. We favour defensive growth going forward (e.g. Health Care, Staples)

Growing uncertainty regarding the impact of high funding costs on the US, European and Global economies for 2023 and 2024. The bottom of the economy should be in H2 2024. Markets are anticipating with a 6 to 12 months advance (somewhere in H2 2023 or H1 2024?). Regarding the bottom, the FED rate cycle will show the way... We are already close

to some distress levels for European small caps.

After China “reopening” comes China “back to structural issues”. The Investor sentiment has turned from China exposure to Artificial Intelligence exposure.

The global IT sector is leading and supporting the equity markets while commodities and Emerging Markets are suffering from the global slowdown and the risks of trade tension with China in a pre-election year in the US.

European Markets are still significantly under owned by global investors and the level of cash of European investors offers some buffer.

Nevertheless, we still expect some weakness of European and Global Equity markets during the next months before starting the next positive Equity market cycle supported by the liquidity of central banks in 2024 and 2025.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website [www.candriam.com](http://www.candriam.com) the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value (“NAV”) of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages <https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/>. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage <https://www.candriam.com/en/professional/market-insights/sfd/>. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act (“FinSA”) and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may be obtained free of charge from the Swiss representative.

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35, CH-1260 Nyon.

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 1493